The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ.
Quackenbush KS, et al. Among authors: gao d.
Oncotarget. 2016 May 10;7(19):28273-85. doi: 10.18632/oncotarget.8626.
Oncotarget. 2016.
PMID: 27070088
Free PMC article.